| |
|
|
|
|
|
|
|||
|
Blood, 15 July 2008, Vol. 112, No. 2, pp. 383-393. Prepublished online as a Blood First Edition Paper on May 8, 2008; DOI 10.1182/blood-2008-01-131185.
NEOPLASIA Down-regulation of TCF8 is involved in the leukemogenesis of adult T-cell leukemia/lymphoma1 Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, 2 Department of Internal Medicine II, University of Miyazaki, Miyazaki; 3 First Department of Pathology, Faculty of Medicine, University of Miyazaki, Miyazaki; 4 Miyazaki Prefectural Industrial Foundation, Miyazaki; 5 Biology Division, National Cancer Center Research Institute, Tokyo; 6 Cancer Genome Project, National Cancer Center Research Institute, Tokyo; 7 Department of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto; 8 Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Miyazaki; 9 Department of Veterinary Pathology, University of Miyazaki, Miyazaki; 10 Department of Digestive and Life-style related Disease, Kagoshima University Graduate School of Medicine and Dental Sciences, Kagoshima; and 11 Graduate School of Frontier Biosciences, Osaka University, Osaka, Japan
Adult T-cell leukemia/lymphoma (ATLL) is caused by latent human T-lymphotropic virus-1 (HTLV-1) infection. To clarify the molecular mechanism underlying leukemogenesis after viral infection, we precisely mapped 605 chromosomal breakpoints in 61 ATLL cases by spectral karyotyping and identified frequent chromosomal breakpoints in 10p11, 14q11, and 14q32. Single nucleotide polymorphism (SNP) array–comparative genomic hybridization (CGH), genetic, and expression analyses of the genes mapped within a common breakpoint cluster region in 10p11.2 revealed that in ATLL cells, transcription factor 8 (TCF8) was frequently disrupted by several mechanisms, including mainly epigenetic dysregulation. TCF8 mutant mice frequently developed invasive CD4+ T-cell lymphomas in the thymus or in ascitic fluid in vivo. Down-regulation of TCF8 expression in ATLL cells in vitro was associated with resistance to transforming growth factor β1 (TGF-β1), a well-known characteristic of ATLL cells, suggesting that escape from TGF-β1–mediated growth inhibition is important in the pathogenesis of ATLL. These findings indicate that TCF8 has a tumor suppressor role in ATLL.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2008 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||